LONDON (Thomson Financial) - GeneMedix Plc. posted a pretax loss of 5.24 million pounds for the year to March 31, 2008, on R&D costs of 2.30 million.

For the 16 months to end-March 2007, the AIM-listed biopharmaceutical company, which is part of the Reliance Life Sciences Group, had a pretax loss of 5.51 million pounds on R&D costs of 3.42 million. TFN.newsdesk@thomson.com jro/slm

COPYRIGHT

Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.